Friday 30 January 2015

Antidepressant market in the US to grow at a CAGR of 4.08% over the period 2014-2019, Finds New Report

Antidepressant Market in the US 2015-2019

Publisher recognizes the following companies as the key players in the Antidepressant Market in the US: Actavis plc, Eli Lilly and Co., GlaxoSmithKline plc, Otsuka Pharmaceutical Co. Ltd. and Pfizer Inc.

Other Prominent Vendors in the market are: Abbott Laboratories, Astrazeneca, Aurobindo Pharma, Bristol-Myers Squibb, Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin, Novartis, Pierre Fabre, Shire, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals.

Commenting on the report, an analyst from Publisher’s team said: “Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which in turn can result in an increase in the overall consumption of medicines.”

According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market.

Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For further information on this report, please visit- http://mrr.cm/4wH

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Investment Opportunities are Plenty in Latin American Hearing Devices Market, New Report Launched

Investment Opportunities are Plenty in Latin American Hearing Devices Market

In Latin America, 4% to 6% of the population is affected by a disabling hearing loss, whereas the rates among North American and European countries are between 2% and 4%, according to World Health Organization estimates. There are approximately 32 million people in Latin America who suffer from mild to severe hearing loss, making up about 9% of the world’s total hearing impaired population.

To address this issue, some countries like Brazil have a public health care program that provides free-of-charge hearing health care services, including diagnosis, treatment, hearing aid distribution, and rehabilitation. However, poor socioeconomic conditions and geographical differences slow down the overall development of hearing healthcare across the region. Current short-term awareness campaigns and the limited number of initiatives by associations and government organizations are insufficient to improve adoption rates.

Low Penetration Rates
The largest segment of the Latin American market for hearing devices is the market for hearing aids, accounting for approximately 750,000 hearing aids sold annually. According to a new report published by iData Research entitled Brazilian Market for Hearing Devices and Batteries, 2015 will see a large proportion of the overall hearing aids sold in Brazil, which represents almost 50% of the entire Latin American market. These numbers reveal how underdeveloped the Latin American market is compared to the U.S., where more than 3 million units are sold on an annual basis.

Relatively low hearing aid usage penetration rates are seen in most developed countries. These rates are even lower in Latin America. In Denmark, where three of the biggest hearing aid manufacturers are based, the adoption rate is approximately 45%. In Europe and the United States, the rates are slightly higher than 22%. But in Brazil, the largest country in Latin America and consequently the biggest Latin American market, only 5% of the hearing-impaired population is using hearing aids. Mexico, the second largest country in Latin America, has a slightly better estimated penetration rate at approximately 9%.

Public Sector As A Market Driver
The public market and government reimbursement plans are some of the biggest drivers for the Latin American hearing device market. Public health care policies help fulfill the need for diagnosis, treatment, and device donations.
Specifically, the majority market share for hearing devices in Brazil, Colombia, and Chile is in the public sector. In Brazil, for example, costs for hearing devices and implants are usually borne by the government.  In 2014, the Unified Health System (Sistema Único de Saúde, or SUS), which is the Brazilian public healthcare network, is expected to provide hundreds of thousands of hearing aids and conduct the majority of all cochlear implant fittings.

Additionally, in June 2014, the Brazilian Ministry of Health published an ordinance to incorporate bone-anchored procedures into the SUS, based on the recommendation report of the National Commission for Incorporation of Technology in SUS (Comissão Nacional de Incorporação de Tecnologias no SUS, or CONITEC). As a result, the bone-anchored hearing aid market in Brazil is expected to experience double-digit growth through 2021.

Nevertheless, the government cannot ensure adequate treatment coverage for the hearing-impaired population in the long term. There is no expectation that the number of devices provided by the public sector will increase significantly; growth rates will continue to be lower than the rates in the private sector. That being the case, hearing health in most of Latin American countries remains highly vulnerable to the changes in government policies and investments.

Lack Of Awareness Remains A Limiting Factor
The rate of hearing aid adoption is still very limited due to a general lack of knowledge and awareness. It is estimated that hearing-impaired individuals wait nearly 10 years on average before seeking treatment after their initial diagnosis. Hearing aid adoption is more frequent in patients with moderate to severe hearing loss.

Aesthetic concerns also contribute to the low rate of adoption. Many patients avoid hearing aids in order to conform to perceived social pressures. Despite the many new hearing aid styles and discreet designs, some still regard hearing aids as a symbol of advanced old age and incapacity. These attitudes and concerns will continue to limit overall hearing aid market growth.

In an attempt to change this perception, the hearing aid industry has been promoting campaigns and initiatives to raise patient awareness. Some manufacturers feature hearing centers dedicated to providing information, education, screening, counseling, support, and technology solutions for people with hearing loss. However, more needs to be done. Larger and longer-term investments can only be made by associations or government organizations.

Holding Groups Lead Latin American Hearing Device Markets

Large holding companies operating within the hearing device market have a strong influence in Latin America. Each holding company owns several individual brands in various market segments. These include the Sonova Group, William Demant Holding Group, and GN Store Nord.

Sonova operates out of Switzerland and holds the Phonak, Argosy, Unitron, and Advanced Bionics hearing aid brands. William Demant operates out of Denmark and holds the Oticon, Oticon Medical, Sonic, and Bernafon hearing aid brands. GN Store Nord also operates out of Denmark and holds the ReSound, Beltone, and Interton hearing aid brands. Other notable competitors in the hearing market include Cochlear, MED-EL, Siemens, Starkey, and Widex.

Each brand is often regarded as a separate entity, but as a group, they can usually offer a complete solution for clinics. Trading premium hearing products like implantable devices, audiometers, tympanometers, and otoacoustic emissions analyzers coupled with hearing aids, holding companies can offer more attractive bundles with a significantly lower average selling price.
Sonova Group leads the Brazilian hearing aid market with the Phonak brand. Today, Brazil is one of Sonova’s top 10 markets by revenue. The country accounts for approximately 4% of group sales, with strong double-digit sales growth in local currencies.

See more about this Blog:  http://mrr.cm/4wr

Know more in details:

Mexican Market for Hearing Devices and Batteries - 2015, visit at:  http://mrr.cm/43f

Brazilian Market for Hearing Devices and Batteries - 2015, visit at:  http://mrr.cm/43N

Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market, New Report Launched

Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market

China’s regulatory framework for medical devices is undergoing radical changes. China is one of the fastest growing global economies with a fifth population in the world, and is one of the largest healthcare markets around the world. Along with sustained economic and population growth as well as an ageing population, Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. Among them, medical devices represented dynamical growth since 2000s. By 2013, total value of medical devices on Chinese healthcare market has reached 179 billion RMB. Medical devices have been widely used in the process of disease prevention, diagnosis, therapy, care and rehabilitation. On the Chinese medical device market, imported overseas medical devices made by overseas and multinational medical device manufacturers account for about a half, in which the high-tech and high-valued medical devices, such as magnetic resonance imaging, CT are almost monopolized by GE, Siemens, Philips and other overseas and multinational companies. It is estimated that Chinese medical device market will be likely to be more than 340 billion RMB by 2015, and will surpass Japan to become the second largest medical device market behind the United States.

The Chinese medical device market is attracting more and more overseas medical device manufacturers and producers to penetrate such market.

Chinese regulatory authorities ---- China Food and Drug Administration unprecedentedly set a special examination and approval procedures for innovative medical devices since March 1, 2014, which provides a opportunity to speed up overseas innovative medical devices entry into Chinese market, and reduce risk from the registration examination uncertainty and approval delays to eat up your time and energy. Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market provided a comprehensive and thorough knowledge of the latest Chinese special examination and approval procedures for innovative medical devices to guide your practical operation how to comply with the Chinese regulations.

The organizations of this guidebook are arranged as follows. Chapter 2 introduces what innovative medical devices are applicable to Chinese special examination and approval procedures. Chapter 3 introduces who are the Chinese regulatory authorities for special examination and approval of overseas innovative medical devices. Chapter 4 elaborates the special regulations for overseas applicant. Chapter 5 introduces how many application dossiers for an oversea innovative medical device should be prepared. Chapter 6 provides the practical guidance for application of special examination and approval of overseas innovative medical devices. Chapter 7 elaborates the benefits from special examination and approval of innovative medical devices: process priority and interactive mechanism. Chapter 8 conclusion gives significant suggestions for overseas and multinational medical device manufacturers to acquire the qualifications of special examination and approval for overseas innovative medical devices.

The audiences of this guidebook are overseas medical device manufacturers wishing to enter into the Chinese medical device market, and multinational medical device companies have penetrated into the Chinese medical device market, and their senior executive officers engaging in regulatory affairs expecting to understand how to apply for registration of their medical device products in China, how to comply with the latest Chinese regulations for medical device registration.

After having skimmed through this guidebook, audiences can clearly acquire not only a comprehensive and thorough knowledge of the latest Chinese special examination and approval of overseas innovative medical devices but also the practical operation how to comply with the latest Chinese special examination and approval of overseas innovative medical devices. Publisher hopes this guidebook, based on full and accurate regulations, can guide overseas and multinational medical device manufacturers and producers to achieve a successful entry into the Chinese medical device market, and smoothly operate their products in China.

Scope
Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market provided a comprehensive and thorough knowledge of the latest Chinese special examination and approval procedures for innovative medical devices to guide overseas and multinational medical device manufacturers how to conduct practical operation in compliance with the Chinese regulations.

Reasons to Buy
  • Chinese regulatory authorities ---- China Food and Drug Administration unprecedentedly set a special examination and approval procedures for innovative medical devices since March 1, 2014, which provides a opportunity to speed up overseas innovative medical devices entry into Chinese market, and reduce risk from the registration examination uncertainty and approval delays to eat up your time and energy. How to grasp the opportunity to speed up your innovative medical device product approval time? The overseas and multinational medical device manufacturers must have a comprehensive and thorough knowledge of the Chinese special examination and approval procedures for innovative medical devices.
  • Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market provided a comprehensive and thorough knowledge of the latest Chinese special examination and approval procedures for innovative medical devices to guide overseas and multinational medical device manufacturers how to conduct practical operation in compliance with the Chinese regulations.


Key Highlights
  • What innovative medical devices are applicable to Chinese special examination and approval procedures.
  • Who are the Chinese regulatory authorities for special examination and approval of overseas innovative medical devices?
  • The Chinese special regulations for overseas applicant.
  • How many application dossiers for an oversea innovative medical device should be prepared.
  • The detailed practical guidance for application of special examination and approval of overseas innovative medical devices to smoothly navigate complex regulatory requirements step by step.
  • What are the benefits from Special Examination and Approval of Innovative Medical Devices: Process Priority and Interactive Mechanism?
  • The significant suggestions for overseas and multinational medical device manufacturers to acquire the qualifications of special examination and approval for overseas innovative medical devices.


Spanning over 32 pages, Chinese Special Examination and Approval Procedures for Innovative Medical Devices: speed up overseas innovative medical devices entry into Chinese market” report covering the Executive Summary, What Innovative Medical Devices are Applicable to Chinese Special Examination and Approval Procedures, Who are Chinese Regulatory Authorities for Special Examination and Approval of Overseas Innovative Medical Devices, Special Regulations for Overseas Applicant, How Many Application Dossiers for Oversea Innovative Medical Device should be Prepared, Application Form for Special Examination and Approval of Innovative Medical Device, Practical Guidance for Application of Special Examination and Approval of Overseas Innovative Medical Devices, What are the benefits from Special Examination and Approval of Innovative Medical Devices: Process Priority and Interactive Mechanism, Conclusion. The report covered companies are - GE, Siemens, Philips

Know more about this report athttp://mrr.cm/4wK

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Thursday 29 January 2015

Wound Care - Traditonal, Advanced and Regenerative - Global Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts, New Report Launched

Wound Care - Traditonal, Advanced and Regenerative - Global Markets, Competitors and Opportunities: 2015-2020 Analysis and Forecasts

A major study and financial analysis of Traditional, Advanced and Regenerative Wound Care markets during the 2015 to 2020 period.

The report focuses on the major classes of Wound Care products: Traditional (sutures, bandages, tape, etc.), Advanced (antimicrobial, alginate, foam, hydrogel, hydrocolloid dressings) and Regenerative (bioengineered skin, skin substitutes). The market for these products is large and some segments are growing rapidly. Competition is intense and the industry is consolidating.

In addition, reimbursement is changing from the current pay-for-service model, in which the treating physician bills the government based on the number and type of procedures performed, to a pay-for-performance model in which reimbursement is fixed for a given diagnosis. This change, intended to incentivize physicians to pursue the most cost-effective treatment modalities and minimize the U.S. health bill, will dramatically change the Wound Care market by shifting market share away from high-tech products with little demonstrated therapeutic benefit to those with more cost-effective solutions.

The report provides comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled.

It is a must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. It is the only published report of its kind, with in-depth detail not found elsewhere in similar studies.

Spanning over 202 pages, Wound Care-Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities:2015-2020 Analysis And Forecasts” report covering the Executive Summary, Introduction, Wound Healing, Wound Care Market, Company Profiles.

Know more about this report athttp://mrr.cm/4w2

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Wednesday 28 January 2015

Gene Therapy Central Nervous System Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape, New Report Launched

Gene Therapy Central Nervous System Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape

Gene Therapy Central Nervous System Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Central Nervous System Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety Publisher Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

Report facts
Gene Therapy Central Nervous System Report: “Gene Therapy Central Nervous System Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” provides in depth insights into the Central Nervous System gene therapy. It has covered 50+ gene therapies covering 30+ Pharmaceutical companies. Studies are performed for approximately 30+ specific indications under Central Nervous System. The Companies are utilizing 22 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 70% for viral vectors, 21% for RNAi therapeutics and 9% for Non Viral vectors. The Report is also giving early winners of the Central Nervous System gene therapy market using Publisher proprietary Matrix Model.

Reports Highlights:
  • Global Gene Therapy Overview & Pipeline Insights
  • Trends in gene therapy partnering deals
  • Current Prominent Research Areas and Key Players
  • Companies Targeting Prominent Therapeutic Areas
  • Number of Gene Therapies in Clinical Trials
  • Number of Gene Therapies by Vectors used
  • Technology and their innovative Companies
  • Early Market Winners for Gene Therapy


Scope
  • A snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy.
  • A review of the marketed Gene therapy products and marketing status
  • Coverage of global gene therapies under development across the globe covering territories
  • Competitive landscape of investigational products for key players and key therapy areas.
  • The Gene Therapy report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
  • The Report also provides the pre-clinical and clinical outcomes of the gene therapies
  • The Report has covered the vector used, target genes, localization of gene and detailed mechanism of action
  • Report has highlighted the licensing opportunities and funding details for gene therapies
  • The report also gives the information of dormant and discontinued pipeline projects
  • Market Analytics of Gene Therapies using Publisher Propriety Model.


Reason to Buy
  • Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy
  • Devise corrective measures for pipeline projects by understanding Therapy area specific gene therapies
  • Developing strategic initiatives to support your gene therapy development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
  • Identifying the upcoming leaders in the gene therapy market in the coming years.
  • Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.


Spanning over 160 pages, Gene Therapy Central Nervous System Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” report covering the Introduction, Global Gene Therapy Market & Pipeline Insight Market Highlight, Gene Therapy- An Upcoming Innovation of Genetic Medicines, Market Manacles for Gene Therapy, Technology Description, Gene Therapies Profiles, Report Methodology.

Know more about this report athttp://mrr.cm/4w3

Gene Therapy Cardiovascular Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape, New Report Launched

Gene Therapy Cardiovascular Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape

Gene Therapy Cardiovascular Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Cardiovascular Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety Publisher Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

Report facts
Gene Therapy Cardiovascular Report: “Gene Therapy Cardiovascular Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” provides in depth insights into the Cardiovascular gene therapy. It has covered 25+ gene therapies covering 20+ Pharmaceutical companies. Studies are performed for approximately 15+ specific indications under Cardiovascular. The Companies are utilizing 8 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 46% for viral vectors, 4% for RNAi Therapeutics and 50% for Non Viral vectors. The Report is also giving early winners of the Cardiovascular gene therapy market using Publisher proprietary Matrix Model.

Reports Highlights:
  • Global Gene Therapy Overview & Pipeline Insights
  • Trends in gene therapy partnering deals
  • Current Prominent Research Areas and Key Players
  • Companies Targeting Prominent Therapeutic Areas
  • Number of Gene Therapies in Clinical Trials
  • Number of Gene Therapies by Vectors used
  • Technology and their innovative Companies
  • Early Market Winners for Gene Therapy


Scope
  • A snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy.
  • A review of the marketed Gene therapy products and marketing status
  • Coverage of global gene therapies under development across the globe covering territories
  • Competitive landscape of investigational products for key players and key therapy areas.
  • The Gene Therapy report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
  • The Report also provides the pre-clinical and clinical outcomes of the gene therapies
  • The Report has covered the vector used, target genes, localization of gene and detailed mechanism of action
  • Report has highlighted the licensing opportunities and funding details for gene therapies
  • The report also gives the information of dormant and discontinued pipeline projects
  • Market Analytics of Gene Therapies using Publisher Propriety Model.


Reason to Buy
  • Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy
  • Devise corrective measures for pipeline projects by understanding Therapy area specific gene therapies
  • Developing strategic initiatives to support your gene therapy development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
  • Identifying the upcoming leaders in the gene therapy market in the coming years.
  • Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.


Spanning over 100 pages, Gene Therapy Cardiovascular Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” report covering the Introduction, Global Gene Therapy Market & Pipeline Insight Market Highlight, Gene Therapy- An Upcoming Innovation of Genetic Medicines, Market Manacles for Gene Therapy, Technology Description, Gene Therapies Profiles, Report Methodology.

Know more about this report athttp://mrr.cm/4w5

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Tuesday 20 January 2015

Global Cancer Biomarkers Market 2015-2019, New Report Launched

Global Cancer Biomarkers Market 2015-2019

Report forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening.  The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
  • Americas
  • APAC
  • EMEA       


Key Vendors
  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen 
  • Quest Diagnostics
  • Roche Diagnostics


Other Prominent Vendors
  • Agendia
  • Agilent Technologies
  • Alere
  • Ambry Genetics
  • Amgen
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • Atossa Genetics
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Biocurex
  • bioMérieux
  • Celldex Therapeutics
  • Clarient
  • diaDexus
  • DiagnoCure
  • Epigenomics
  • EUSA Pharma
  • Exact Sciences
  • Foundation Medicine
  • Fujirebio Diagnostics
  • Genomic Health
  • Geron
  • Immunomedics
  • Morphotek
  • Myriad Genetics
  • Nodality
  • Northwest Biotherapeutics
  • Ocimum Biosolutions
  • Oncothyreon
  • OriGene
  • Polymedco
  • Radient Pharmaceuticals
  • Randox Laboratories
  • Siemens Healthcare
  • US Biomarkers
  • Vermillion


Market Driver
  • Increased Prevalence of Cancer
  • For a full, detailed list, view our report


Market Challenge
  • Regulatory and Reimbursement Issues
  • For a full, detailed list, view our report


Market Trend
  • Growing Popularity of Companion Diagnostics
  • For a full, detailed list, view our report


Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Spanning over 89 pages, Global Cancer Biomarkers Market 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Incidence and Prevalence, Biomarkers Used in Cancer Diagnosis, FDA Approval Process for Protein-Based Cancer Biomarkers, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are - Abbott Laboratories,  Affymetrix,  Illumina,  Qiagen ,  Quest Diagnostics, Roche Diagnostics, Agendia,  Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US,  Astex Pharmaceuticals, Atossa Genetics,  Beckman Coulter, Becton, Dickinson and Company,

Know more about this report athttp://mrr.cm/4Uu

Find all Diagnostics Reports at: http://www.marketresearchreports.com/diagnostics

Commercial Vehicle Telematics Market in the Americas 2015-2019, New Report Launched

Commercial Vehicle Telematics Market in the Americas 2015-2019

Report forecast the Commercial Vehicle Telematics market in the Americas to grow at a CAGR of 16.68 percent over the period 2014-2019.

Telematics is a term used to describe the wireless connectivity between motor vehicles and the infrastructure where the receiving equipment is installed. Telematics is an integrated technology wherein telecommunication and IT are combined to provide a single solution. Telematics uses telecom equipment to send, receive, and store information in a vehicle. The connectivity can be machine-to-machine or machine-to-human. This technology is used primarily for tracking and communication. It can be either integrated with various other systems of the vehicle or used separately and operated using mobile applications. Telematics is used in applications such as vehicle tracking, satellite navigation, emergency warning systems, and fleet management systems. Telematics also plays a major role in providing improved security to drivers and passengers.

This report covers the present scenario and the growth prospects of the Commercial Vehicle Telematics market in the Americas for the period 2015-2019. There are three types of commercial vehicle telematics systems available in the market: Embedded telematics systems, portable telematics systems, and smartphone-based telematics systems. The report discusses the fleet operation costs and the benefits of fleet management systems, along with the cost of distribution of different types of commercial telematics systems.

In addition, this report covers the entire range of telematics for LCVs, MCVs, and HCVs available in the Commercial Vehicle Telematics market in the Americas. It also presents the vendor landscape and a corresponding detailed analysis of the top seven vendors in the Commercial Vehicle Telematics market in the Americas. In addition, the report includes the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as key trends that are emerging in the market.

Commercial Vehicle Telematics Market in Americas 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas; it also covers the landscape of the Commercial Vehicle Telematics market in the Americas and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
  • Americas


Key Vendors
  • AirIQ
  • Fleetmatics Group
  • Omnitracs
  • OnStar
  • TeleNav
  • TomTom International
  • Trimble Navigation


Other Prominent Vendors
  • Actsoft
  • Applied Telematics
  • ARI
  • Autotrac
  • Blue Tree Systems
  • BSM Wireless
  • Cadec Global
  • CarrierWeb
  • Celtrak
  • Chevin
  • CMC
  • Ctrack
  • Diamler Fleetboard
  • Digicore
  • DriverTech
  • EDT
  • FieldLogix
  • Fleetcor Technologies
  • Fleetio
  • Garmin International
  • Google
  • GPS Integrated
  • GPSTrackIt
  • HUGHES Telematics
  • ID Systems
  • iMetrik Solutions
  • Inosat Global
  • Intelligent Mechatronic Systems
  • International Telematics
  • Isotrak
  • iTrack
  • Kore Telematics
  • Masternaut
  • Navman Wireless
  • Octo Telematics
  • OnixSat
  • ORTEC
  • Qualcomm
  • SkyBitz
  • Teletrac
  • Telogis
  • Telular
  • TrakM8
  • Verizon
  • Webtech Wireless
  • WirelessCar
  • Wireless Matrix
  • XRS
  • Zatix
  • Zonar Systems


Market Driver
  • Need for Efficient Data Management
  • For a full, detailed list, view our report


Market Challenge
  • Data Security-related Issues
  • For a full, detailed list, view our report


Market Trend
  • Increase in Use of Cloud-based Telematics
  • For a full, detailed list, view our report


Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Spanning over 93 pages, Commercial Vehicle Telematics Market in the Americas 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Buying Criteria, Geographical Segmentation, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are - AirIQ , Fleetmatics Group , Omnitracs , OnStar , TeleNav , TomTom International, Trimble Navigation , Actsoft, Applied Telematics, ARI , Autotrac, Blue Tree Systems, BSM Wireless, Cadec Global, CarrierWeb, Celtrak, Chevin, CMC , Ctrack, Diamler Fleetboard, Digicore,DriverTech, EDT, FieldLogix, Fleetcor Technologies, Fleetio, Garmin International, Google, GPS Integrated, GPSTrackIt, HUGHES Telematics.

Know more about this report athhttp://mrr.cm/4UX

Find all IT and eHealth Reports at: http://www.marketresearchreports.com/it-ehealth

Active Pharmaceutical Ingredients (API) Market in India 2015-2019, New Report Launched

Active Pharmaceutical Ingredients (API) Market in India 2015-2019

Report forecast the API market in India to grow at a CAGR of 10.76 percent over the period 2014-2019.

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology, respiratory disorders, and rheumatoid arthritis.

This report covers the present scenario and the growth prospects of the API market in India during the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of API by vendors in the market. The report provides the vendor landscape and a corresponding detailed analysis of the top three vendors in the market. The market segmentation data and analysis is also provided for the following segmentation types: type of production process and area of therapy.

In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
The API Market in India 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

Key Vendors
  • Aurobindo Pharma
  • Cipla
  • Dr. Reddy's Laboratories


Other Prominent Vendors
  • Anuh Pharma
  • Alembic Pharmaceuticals
  • A. R. Life Sciences
  • Atul Bioscience
  • Biocon
  • Cadila Pharmaceuticals
  • Calyx Chemicals & Pharmaceuticals
  • CIRON Drugs and Pharmaceuticals
  • CTX Life Sciences
  • Dishman Pharmaceuticals & Chemicals
  • Elder Pharmaceuticals
  • Emcure Pharmaceuticals
  • FDC
  • Glenmark Pharmaceuticals
  • Hetero Drugs
  • Hikal
  • Ind-Swift Laboratories
  • Ipca Laboratories
  • J. B. Chemicals and Pharmaceuticals
  • Laurus Labs
  • Lupin
  • Mangalam Drugs & Organics
  • Mylan Laboratories
  • Orchid Chemicals and Pharmaceuticals
  • Ranbaxy Laboratories
  • Sandoz
  • Sequent Scientific
  • Shasun Pharmaceuticals
  • Sterling Biotech
  • Sun Pharmaceutical Industries
  • The Piramal Group
  • Torrent Pharmaceuticals
  • Unichem Laboratories
  • Wockhardt


Market Driver
  • Strong Preference for Generic Drugs
  • For a full, detailed list, view our report


Market Challenge
  • Regulatory Ban
  • For a full, detailed list, view our report


Market Trend
  • Emergence of Africa
  • For a full, detailed list, view our report


Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Spanning over 64 pages, Active Pharmaceutical Ingredients (API) Market in India 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, API Market in India, Market Segmentation by Type of Production Process, Market Segmentation by Area of Therapy, Key Vendor Analysis. The report covered companies are - Aurobindo Pharma, Cipla, Dr. Reddy's Laboratories , Anuh Pharma, Alembic Pharmaceuticals, A. R. Life Sciences, Atul Bioscience, Biocon, Cadila Pharmaceuticals, Calyx Chemicals & Pharmaceutical, CIRON Drugs and Pharmaceuticals, CTX Life Sciences , DishmanPharmaceuticals & Chemicals, Elder Pharmaceuticals, Emcure Pharmaceuticals, FDC, Glenmark Pharmaceuticals, Hetero Drug, Hikal, Ind-Swift Laboratories, Ipca Laboratories, J. B. Chemicals and Pharmaceuticals, Laurus Labs, Lupin, Mangalam Drugs & Organics,Mylan Laboratories, Orchid Chemicals and Pharmaceuticals, Ranbaxy Laboratories, Sandoz, Sequent Scientific, Shasun Pharmaceuticals, Sterling Biotech, Sun Pharmaceutical Industries, The Piramal Group, Torrent Pharmaceuticals, Unichem Laboratories, Wockhardt

Know more about this report athttp://mrr.cm/4U7

Find all Pharmaceutical Manufacturing Reports at: